Potential reasons for the lower in vivo levels obtained for nivolumab include, apart from the use of vectors in the single-stranded configuration, immune reactions against the human antibody, and enhanced diffusion of the AAV-encoded nivolumab into blood vessels due to low abundance of target cells (lymphocytes expressing human PD-1) in the selected tumor model. The gene discussed is PDCD1; the disease is neoplasm.